Merck KGaA completes acquisition of SpringWorks Therapeutics for $47.00 per share

SpringWorks Therapeutics, Inc.

Merger closed on July 1, 2025; SpringWorks becomes wholly owned subsidiary of Merck KGaA.
Shareholders received $47.00 per share in cash; shares of SWTX delisted from Nasdaq.
Board of directors and officers resigned; new directors and officers appointed by Merck KGaA.
Certificate of incorporation and bylaws amended and restated effective at closing.

item 2.01item 3.01item 3.03item 5.01item 5.02item 5.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.